In Vitro Evaluation of Valproic Acid As an Inhibitor of Human Cytochrome P450 Isoforms: Preferential Inhibition of Cytochrome P450 2C9 (CYP2C9)

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2001 Dec 12

PMID 11736863

Citations 43

Authors

X Wen

J S Wang

K T Kivisto

P J Neuvonen

J T Backman

Affiliations

Soon will be listed here.

Abstract

Aims: To evaluate the potency and specificity of valproic acid as an inhibitor of the activity of different human CYP isoforms in liver microsomes.

Methods: Using pooled human liver microsomes, the effects of valproic acid on seven CYP isoform specific marker reactions were measured: phenacetin O-deethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), tolbutamide hydroxylase (CYP2C9), S-mephenytoin 4'-hydroxylase (CYP2C19), dextromethorphan O-demethylase (CYP2D6), chlorzoxazone 6-hydroxylase (CYP2E1) and midazolam 1'-hydroxylase (CYP3A4).

Results: Valproic acid competitively inhibited CYP2C9 activity with a Ki value of 600 microM. In addition, valproic acid slightly inhibited CYP2C19 activity (Ki = 8553 microM, mixed inhibition) and CYP3A4 activity (Ki = 7975 microM, competitive inhibition). The inhibition of CYP2A6 activity by valproic acid was time-, concentration- and NADPH-dependent (KI = 9150 microM, Kinact=0.048 min(-1)), consistent with mechanism-based inhibition of CYP2A6. However, minimal inhibition of CYP1A2, CYP2D6 and CYP2E1 activities was observed.

Conclusions: Valproic acid inhibits the activity of CYP2C9 at clinically relevant concentrations in human liver microsomes. Inhibition of CYP2C9 can explain some of the effects of valproic acid on the pharmacokinetics of other drugs, such as phenytoin. Co-administration of high doses of valproic acid with drugs that are primarily metabolized by CYP2C9 may result in significant drug interactions.

Citing Articles

Utilizing an acute hyperthermia-induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome.

Mensah J, Johnson K, Freeman T, Reilly C, Rower J, Metcalf C Epilepsia. 2024; 65(10):3100-3114.

PMID: 39212337 PMC: 11496002. DOI: 10.1111/epi.18104.

Therapeutic drug monitoring of free perampanel concentrations in practice: A practical analytical technique based on centrifugal ultrafiltration sample separation.

Ma Y, Dong L, Wu J, Hu S, Meng X, Zhao Y Heliyon. 2024; 10(15):e35734.

PMID: 39170259 PMC: 11336813. DOI: 10.1016/j.heliyon.2024.e35734.

Management Challenges and Potential Malabsorption of Valproic Acid in a Patient with Bipolar Disorder and Gastrointestinal History.

Kwok J, Wong J, Kim K Case Rep Psychiatry. 2024; 2024:1426930.

PMID: 39105207 PMC: 11300106. DOI: 10.1155/2024/1426930.

Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients.

Bao S, Yang S, Hua Z, Li J, Zang Y, Li X Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9811-9821.

PMID: 38918237 DOI: 10.1007/s00210-024-03244-y.

Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients.

Ansermot N, Vathanarasa H, Ranjbar S, Gholam M, Crettol S, Vandenberghe F Ther Drug Monit. 2024; .

PMID: 38833576 PMC: 11554250. DOI: 10.1097/FTD.0000000000001227.

References

WESTER M, Lasker J, Johnson E, Raucy J . CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos. 2000; 28(3):354-9. View

Hesslinger B, Normann C, Langosch J, Klose P, Berger M, Walden J . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1999; 19(4):310-5. DOI: 10.1097/00004714-199908000-00005. View

Fehr C, Grunder G, Hiemke C, Dahmen N . Increase in serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol. 2000; 20(4):493-4. DOI: 10.1097/00004714-200008000-00019. View

Ward E, Pollack G, Brouwer K . Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?. Drug Metab Dispos. 2000; 28(12):1433-9. View

Bruni J, Wilder B, Perchalski R, Hammond E, Villarreal H . Valproic acid and plasma levels of phenobarbital. Neurology. 1980; 30(1):94-7. DOI: 10.1212/wnl.30.1.94. View

Patel I, Levy R, Cutler R . Phenobarbital--valporic acid interaction. Clin Pharmacol Ther. 1980; 27(4):515-21. DOI: 10.1038/clpt.1980.72. View

Bruni J, Gallo J, Lee C, Perchalski R, Wilder B . Interactions of valproic acid with phenytoin. Neurology. 1980; 30(11):1233-6. DOI: 10.1212/wnl.30.11.1233. View

Perucca E, Hebdige S, Frigo G, Gatti G, Lecchini S, Crema A . Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther. 1980; 28(6):779-89. DOI: 10.1038/clpt.1980.235. View

Suganuma T, Ishizaki T, Chiba K, Hori M . The effect of concurrent administration of valproate sodium on phenobarbital plasma concentration/dosage ratio in pediatric patients. J Pediatr. 1981; 99(2):314-7. DOI: 10.1016/s0022-3476(81)80488-x. View

10.

Dhillon S, Richens A . Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol. 1982; 13(4):553-60. PMC: 1402061. DOI: 10.1111/j.1365-2125.1982.tb01421.x. View

11.

Levy R, Koch K . Drug interactions with valproic acid. Drugs. 1982; 24(6):543-56. DOI: 10.2165/00003495-198224060-00004. View

12.

Motulsky H, Ransnas L . Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1987; 1(5):365-74. View

13.

Wietholtz H, Zysset T, Kreiten K, Kohl D, Buchsel R, Matern S . Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol. 1989; 36(4):401-6. DOI: 10.1007/BF00558303. View

14.

Aberg-Wistedt A, Bertilsson L . Glucuronidation of amitriptyline in man in vivo. Pharmacol Toxicol. 1989; 65(1):37-9. DOI: 10.1111/j.1600-0773.1989.tb01123.x. View

15.

Broly F, Libersa C, Lhermitte M, Dupuis B . Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol. 1990; 39(6):1045-53. DOI: 10.1016/0006-2952(90)90283-q. View

16.

Levy R, Rettenmeier A, Anderson G, Wilensky A, Friel P, Baillie T . Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther. 1990; 48(3):225-35. DOI: 10.1038/clpt.1990.144. View

17.

Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G . Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos. 1990; 18(5):595-606. View

18.

Tartara A, Galimberti C, Manni R, Parietti L, Zucca C, Baasch H . Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol. 1991; 32(3):335-40. PMC: 1368527. DOI: 10.1111/j.1365-2125.1991.tb03908.x. View

19.

Yuen A, Land G, Weatherley B, Peck A . Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992; 33(5):511-3. PMC: 1381438. DOI: 10.1111/j.1365-2125.1992.tb04079.x. View

20.

Liu M, Brouwer K, Pollack G . Pharmacokinetics and pharmacodynamics of valproate analogs in rats. III. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat. Drug Metab Dispos. 1992; 20(6):810-5. View